Merck respiratory goes to McCann

Share this article:
Schirmer: Merck is an "extremely important" client
Schirmer: Merck is an "extremely important" client

McCann HumanCare landed the agency of record assignment for consumer advertising and communications on Merck's respiratory franchise, which includes Nasonex, Singulair and Dulera.

The business will be led by EVP managing director Andrew Schirmer, who said in a statement: “Merck is an extremely important new client for our group and we are proud and excited to be named as one of their key marketing solutions partners.”

McCann landed the business as part of a larger Interpublic win in November. Draftfcb's Agency 23 served as lead agency on the pitch. The assignment spanned professional and consumer advertising, med ed and managed care for asthma, allergy and COPD brands. It was previously split between several Omnicom shops, with BBDO tasked with consumer advertising on Nasonex and DDB handling Dulera. Also included in the assignment was Merck's investigational oral allergy immunotherapy tablet, now in Phase III clinical trials. Draftfcb handles the professional advertising business on Merck's cardiovascular and metabolic franchise, including Januvia.

It's not all bad for Omnicom, either, as the holding company recently won Merck business in the cardiovascular, oncology, contraception, fertility, immunology and bone-therapeutic categories, with DDB heading up consumer advertising on those accounts, according to Ad Age.

Merck was the third biggest spender on DTC for the year to October 2010, according to SDI/Kantar data we reported in April 2011. The company, which acquired Nasonex along with Schering-Plough, spent $349 million, or 8.3% of total industry spending on consumer advertising, for that period. Spending on the company's respiratory portfolio probably accounted for around a third of that.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Headliner: Ipsen head leads continental charge

Headliner: Ipsen head leads continental charge

"When I look at the business, I actually see patients in my mind. I don't see numbers."

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets